1 completed. 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Completed 1 |
Follow Amr Mohamed MD: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| NP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine Carcinomas NP-101 (TQ Formula), Nivolumab (3mg/kg), Ipilimumab (1mg/kg) - Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Neoplasm | Phase 1 | Completed | Amr Mohamed MD | 15 | 2022-12-15 | 2026-08-10 |
Carcinoma, Neuroendocrine (1) · Gastro-enteropancreatic neuroendocrine tumor (1)
Ipilimumab (1) · Nivolumab (1)
United States (1)
Amr Mohamed, MD (1)